Recombinant IL-6R (Tocilizumab Biosimilar) antibody

Catalog No. ABIN5668253

Product Details anti-IL-6R (Tocilizumab Biosimilar) Antibody

Target: IL-6R (Tocilizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Human

Clonality: Monoclonal

Conjugate: This IL-6R (Tocilizumab Biosimilar) antibody is un-conjugated

Application: ELISA, Inhibition Assay (InhA)

Purpose: Anti-IL-6 receptor [rhPM-1 (Tocilizumab)], Human IgG1, kappa

Specificity: Tocilizumab binds specifically to both the membrane bound and soluble forms of human IL-6R. The IL6 receptor is a protein complex consisting of an IL-6 receptor subunit (IL6R) and interleukin 6 signal transducer Glycoprotein 130. Interleukin 6 (IL6) is a potent pleiotropic cytokine that regulates cell growth and differentiation and plays an important role in immune response.

Characteristics:

Original Species of Ab: Human

Original Format of Ab: IgG1

Purification: Protein A affinity purified

Purity: > 98 % as determined by SDS-PAGE

Endotoxin Level: Endotoxin is < 1.0 EU/mg as determined by the LAL method

Immunogen: The original antibody was generated by CDR grafting of mouse PM-1 antibody onto human REI and NEW framework regions to create rhPM-1.

Clone: RhPM-1

Isotype: IgG1 kappa

Application Details

Application Notes: This antibody is derived from the parental mouse clone PM-1 (PM1). Tocilizumab (TCZ) binds and neutralizes IL-6R, resulting in the inhibition of various IL-6-mediated biological activities, including inflammation-related, immunomodulatory and tissue/matrix remodelling effects. This antibody is extensively explored for its therapeutic potential in treatment of rheumatoid arthritis (PMID: 25099958, 9836380). Tocilizumab can be used in ELISA assays and is able to inhibit the growth of IL-6-dependent tumor cell lines. It inhibits sIL-6R and mIL-6R-mediated signaling. A study reported that a combination of tocilizumab and methotrexate (MTX) results in greater inhibition of joint damage and improvement in physical function than does MTX alone (PMID: 21360490). Treatment with tocilizumab results in significant improvement, maintained over time, of polyarticular-course juvenile idiopathic arthritis (pcJIA) signs and symptoms and has a safety profile consistent with that for adults with rheumatoid arthritis (PMID: 24834925). The original antibody was used for an in vivo study on ALS. Here they showed that this antibody does not affect all patients the same way. Here it was shown that the antibody lowers inflammation in patients with high inflammation and increases inflammation in patients with low inflammation (Fiala et al., 2013, PMID:23844337). tocilizumab inhibited both the transcription and secretion of cytokines and chemokines induced by apo-G37R. This showed powerful effects on the inflammation in ALS PMBC (Mizwicki et al., 2012, PMID: 23383400)

Comment:

NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar.

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

References for anti-IL-6R (Tocilizumab Biosimilar) antibody (ABIN5668253)

Hsieh, Hsu, Chang, Lai: "IL-6 receptor blockade corrects defects of XIAP-deficient regulatory T cells." in: Nature communications, Vol. 9, Issue 1, pp. 463, (2018) (PubMed).

Target Details for IL-6R (Tocilizumab Biosimilar)

Target: IL-6R (Tocilizumab Biosimilar)

Abstract: IL-6R (Tocilizumab Biosimilar) Products

Target Type: Biosimilar

Background: IL6R, IL-6R, CD126, MRA, atlizumab, TCZ, Interleukin-6 receptor subunit alpha, IL-6 receptor subunit alpha, IL-6R subunit alpha, IL-6R-alpha, IL-6RA, IL-6R 1, Membrane glycoprotein 80, gp80, PM1, PM-1

UniProt: P08887